Beyond Next Ventures invests in Kanjin Therapeutics private round

• Beyond Next Ventures invested in Kanjin Therapeutics in a private financing round disclosed on 2026.07.31.
• Kanjin is a California-based biotech with operations in Japan, commercializing Okayama University research to develop kidney disease treatments.
• The company targets a liver-kidney signaling pathway to modulate podocytes, aiming to restore glomerular structure and kidney function.
• Lead program is a nucleic acid therapeutic in preclinical development, focused on FSGS and diabetic nephropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beyond Next Ventures Inc published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.